<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37243319</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-1128</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Medicinal research reviews</Title><ISOAbbreviation>Med Res Rev</ISOAbbreviation></Journal><ArticleTitle>Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2260</StartPage><EndPage>2302</EndPage><MedlinePgn>2260-2302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/med.21974</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease in which the motor neuron circuitry displays progressive degeneration, affecting mostly the motor neurons in the brain and in the spinal cord. There are no effective cures, albeit three drugs, riluzole, edaravone, and AMX0035 (a combination of sodium phenylbutyrate and taurursodiol), have been approved by the Food and Drug Administration, with limited improvement in patients. There is an urgent need to build better and more effective treatment strategies for ALS. Since the disease is very heterogenous, numerous approaches have been explored, such as targeting genetic mutations, decreasing oxidative stress and excitotoxicity, enhancing mitochondrial function and protein degradation mechanisms, and inhibiting neuroinflammation. In addition, various chemical libraries or previously identified drugs have been screened for potential repurposing in the treatment of ALS. Here, we review previous drug discovery efforts targeting a variety of cellular pathologies that occur from genetic mutations that cause ALS, such as mutations in SOD1, C9orf72, FUS, and TARDP-43 genes. These mutations result in protein aggregation, which causes neuronal degeneration. Compounds used to target cellular pathologies that stem from these mutations are discussed and comparisons among different preclinical models are presented. Because the drug discovery landscape for ALS and other motor neuron diseases is changing rapidly, we also offer recommendations for a novel, more effective, direction in ALS drug discovery that could accelerate translation of effective compounds from animals to patients.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elmansy</LastName><ForeName>Mohamed F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0001-9701-6516</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Organometallic and Organometalloid Chemistry, National Research Centre, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reidl</LastName><ForeName>Cory T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahaman</LastName><ForeName>Mizzanoor</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1433-5755</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zdinler</LastName><ForeName>P Hande</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0003-4125-6013</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><Identifier Source="ORCID">0000-0001-9034-1084</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG061708</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Res Rev</MedlineTA><NlmUniqueID>8103150</NlmUniqueID><ISSNLinking>0198-6325</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000723627">sodium phenylbutyrate and taurursodiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cellular pathologies</Keyword><Keyword MajorTopicYN="N">gene mutations</Keyword><Keyword MajorTopicYN="N">inhibition</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword></KeywordList><CoiStatement>CONFLICT OF INTEREST STATEMENT. The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37243319</ArticleId><ArticleId IdType="mid">NIHMS1899011</ArticleId><ArticleId IdType="pmc">PMC10592673</ArticleId><ArticleId IdType="doi">10.1002/med.21974</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364(6435):362.</Citation><ArticleIdList><ArticleId IdType="pubmed">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Bosco DA, LeClerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, van Doormaal PTC, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genet. 2016;48(9):1037&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw CE. Capturing VCP: another molecular piece in the ALS Jigsaw Puzzle. Neuron. 2010;68(5):812&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">21144996</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H-X, Chen W, Hong S-T, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477(7363):211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neurosci. 2015;18(5):631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Zhang Y-J, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4(9):e1000193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527686</ArticleId><ArticleId IdType="pubmed">18802454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genet. 2008;40(5):572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol. 2008;21(6):693&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869081</ArticleId><ArticleId IdType="pubmed">18989115</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervishi I, Gozutok O, Murnan K, et al. Protein-protein interactions reveal key canonical pathways, upstream regulators, interactome domains, and novel targets in ALS. Sci Rep. 2018;8(1):14732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6170493</ArticleId><ArticleId IdType="pubmed">30283000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, Petrucelli L. Genetic convergence brings clarity to the enigmatic red line in ALS. Neuron. 2019;101(6):1057&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">30897357</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Harvey C, Zhang S, et al. Advances in the genetic classification of amyotrophic lateral sclerosis. Curr Opin Neurol. 2021;34(5):756&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612116</ArticleId><ArticleId IdType="pubmed">34343141</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Atienzar S, Dalgard CL, Ding J, et al. Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. Neurology. 2020;95(22):1015&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734922</ArticleId><ArticleId IdType="pubmed">33077544</ArticleId></ArticleIdList></Reference><Reference><Citation>Majcher V, Goode A, James V, Layfield R. Autophagy receptor defects and ALS-FTLD. Mol Cell Neurosci. 2015;66:43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25683489</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus S, Valenzuela V, Medinas DB, Hetz C. ER dysfunction and protein folding stress in ALS. Int J Cell Biol. 2013;2013:674751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845333</ArticleId><ArticleId IdType="pubmed">24324498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue GM, Cleary JD, Guo S, Ranum LPW. Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol. 2021;34(5):748&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8678157</ArticleId><ArticleId IdType="pubmed">34392299</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughlin FE, Wilce JA. TDP-43 and FUS&#x2013;structural insights into RNA recognition and self-association. Curr Opin Struct Biol. 2019;59:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">31479821</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz B, Lee BL, Shorter J. FUS and TDP-43 phases in health and disease. Trends Biochem Sci. 2021;46(7):550&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195841</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich KA, Roggenbuck J, Kolb SJ. Searching far and Genome-Wide: the relevance of association studies in amyotrophic lateral sclerosis. Front Neurosci. 2021;14:603023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873947</ArticleId><ArticleId IdType="pubmed">33584177</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJN, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Greensmith L. Cellular chaperones as therapeutic targets in ALS to restore protein homeostasis and improve cellular function. Front Mol Neurosci. 2017;10:251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5596081</ArticleId><ArticleId IdType="pubmed">28943839</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2017;16(7):505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(Issue 6suppl ment 4):233S&#x2013;241S.</Citation><ArticleIdList><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Manev H, Favaron M, Guidotti A, Costa E. Delayed increase of Ca2+ influx elicited by glutamate: role in neuronal death. Mol Pharmacol. 1989;36(1):106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">2568579</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitoh Y, Takahashi Y. Riluzole for the treatment of amyotrophic lateral sclerosis. Neurodegener Dis Manag. 2020;10(6):343&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">32847483</ArticleId></ArticleIdList></Reference><Reference><Citation>Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Cerebrovasc Dis. 2003;15(3):222&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12715790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz MP. Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P &amp; T. 2018;43(1):25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci[Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874397</ArticleId><ArticleId IdType="pubmed">20552050</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly C, Hecquet P-E, Kouach M, Thuru X, Goossens J-F. Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone. Bioorg Med Chem. 2020;28(10):115463.</Citation><ArticleIdList><ArticleId IdType="pubmed">32241621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fels JA, Dash J, Leslie K, Manfredi G, Kawamata H Effects of the investigational drug sodium phenylbutyrate-TUDCA (AMX0035) on the transcriptional and metabolic landscape of sporadic ALS fibroblasts. bioRxiv 2022;2022.05.02.490306.</Citation></Reference><Reference><Citation>Khalaf K, Tornese P, Cocco A, Albanese A. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener. 2022;11(1):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166453</ArticleId><ArticleId IdType="pubmed">35659112</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo Y-A. Sodium phenylbutyrate and ursodoxicoltaurine: first approval. CNS Drugs. 2022;36(9):1007&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">35907175</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267(4):944&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? The Lancet Neurology. 2014;13(11):1127&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis&#x2014;past, present, and future. Med Res Rev. 2020;40(4):1352&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLoach A, Cozart M, Kiaei A, Kiaei M. A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opin Drug Discovery. 2015;10(10):1099&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">26307158</ArticleId></ArticleIdList></Reference><Reference><Citation>Arti KaurA, Singh M, Arora S, Dhiman S, Satija S, Singh TG. Pharmacotherapy of amyotrophic lateral sclerosis: an insight. Plant Arch. 2019;19:1385&#x2013;1397.</Citation></Reference><Reference><Citation>Kumar V, Islam A, Hassan MI, Ahmad F. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning. Eur J Med Chem. 2016;121:903&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">27372371</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DG, Shorter J, Wobst HJ. Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. Bioorg Med Chem Lett. 2020;30(4):126942.</Citation><ArticleIdList><ArticleId IdType="pubmed">31926785</ArticleId></ArticleIdList></Reference><Reference><Citation>Limpert AS, Mattmann ME, Cosford NDP. Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS). Beilstein J Org Chem. 2013;9:717&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678841</ArticleId><ArticleId IdType="pubmed">23766784</ArticleId></ArticleIdList></Reference><Reference><Citation>Doucette PA, Whitson LJ, Cao X, et al. Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant. J Biol Chem. 2004;279(52):54558&#x2013;54566.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485869</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfonso-Prieto M, Biarn&#xe9;s X, Vidossich P, Rovira C. The molecular mechanism of the catalase reaction. J Am Chem Soc. 2009;131(33):11751&#x2013;11761.</Citation><ArticleIdList><ArticleId IdType="pubmed">19653683</ArticleId></ArticleIdList></Reference><Reference><Citation>McCord JM, Fridovich I. Superoxide dismutase. J Biol Chem. 1969;244(22):6049&#x2013;6055.</Citation><ArticleIdList><ArticleId IdType="pubmed">5389100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruzman A, Wood WL, Alpert E, et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2007;104(30):12524&#x2013;12529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941502</ArticleId><ArticleId IdType="pubmed">17636119</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K, Andersen PM, Marklund SL, Br&#xe4;nnstr&#xf6;m T. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121(5):623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085063</ArticleId><ArticleId IdType="pubmed">21287393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi SA, Urushitani M, Julien J-P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007;102(1):170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Guareschi S, Cova E, Cereda C, et al. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci USA. 2012;109(13):5074&#x2013;5079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3324021</ArticleId><ArticleId IdType="pubmed">22416121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sau D, De Biasi S, Vitellaro-Zuccarello L, et al. Mutation of SOD1 in ALS: a gain of a loss of function. Hum Mol Gen. 2007;16(13):1604&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17504823</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon RA, Bunton-Stasyshyn RKA, Fisher EMC, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136(8):2342&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep. 2006;6(1):37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469270</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine JS, Hart PJ. Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2003;100(7):3617&#x2013;3622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152971</ArticleId><ArticleId IdType="pubmed">12655070</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto G, Stojanovic A, Holmberg CI, Kim S, Morimoto RI. Structural properties and neuronal toxicity of amyotrophic lateral sclerosis&#x2013;associated Cu/Zn superoxide dismutase 1 aggregates. J Cell Biol. 2005;171(1):75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171239</ArticleId><ArticleId IdType="pubmed">16216923</ArticleId></ArticleIdList></Reference><Reference><Citation>Broom WJ, Auwarter KE, Ni J, et al. Two approaches to drug discovery in SOD1-Mediated ALS. SLAS Discovery. 2006;11(7):729&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">16928982</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami G, Inoue H, Tsukita K, et al. Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat amyotrophic lateral sclerosis. SLAS Discovery. 2011;16(4):405&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">21364087</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak RJ, Cuny GD, Choi S, Lansbury PT, Ray SS. Improving binding specificity of pharmacological chaperones that target mutant superoxide Dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010;53(7):2709&#x2013;2718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881568</ArticleId><ArticleId IdType="pubmed">20232802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PD. A high-throughput screen to identify inhibitors of SOD1 transcription. Front Biosci. 2012;E4(8):2701&#x2013;2708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083181</ArticleId><ArticleId IdType="pubmed">22652679</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukas TJ, Schiltz GE, Arrat H, Scheidt K, Siddique T. Discovery of 1,3,4-oxidiazole scaffold compounds as inhibitors of superoxide dismutase expression. Bioorg Med Chem Lett. 2014;24(6):1532&#x2013;1537.</Citation><ArticleIdList><ArticleId IdType="pubmed">24560539</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzai I, Toichi K, Tokuda E, Mukaiyama A, Akiyama S, Furukawa Y. Screening of drugs inhibiting in vitro oligomerization of Cu/Zn-superoxide dismutase with a mutation causing amyotrophic lateral sclerosis. Front Mol Biosci. 2016;3:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977284</ArticleId><ArticleId IdType="pubmed">27556028</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Nandar W, Neely EB, Simmons Z, Connor JR. Statins accelerate disease progression and shorten survival in SOD1 G93A mice. Muscle Nerve. 2016;54(2):284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5848093</ArticleId><ArticleId IdType="pubmed">26799243</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R, Meng H, Wongkongkathep P, et al. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. J Biol Chem. 2019;294(10):3501&#x2013;3513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416427</ArticleId><ArticleId IdType="pubmed">30602569</ArticleId></ArticleIdList></Reference><Reference><Citation>Capper MJ, Wright GSA, Barbieri L, et al. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat Commun. 2018;9(1):1693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5923229</ArticleId><ArticleId IdType="pubmed">29703933</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala FA, Wright GSA, Antonyuk SV, Garratt RC, Hasnain SS. Molecular recognition and maturation of SOD1 by its evolutionarily destabilised cognate chaperone hCCS. PLoS Biol. 2019;17(2):e3000141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6383938</ArticleId><ArticleId IdType="pubmed">30735496</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L, Bertini I, Bla&#x17e;evit&#x161; O, et al. Interaction of cisplatin with human superoxide dismutase. J Am Chem Soc. 2012;134(16):7009&#x2013;7014.</Citation><ArticleIdList><ArticleId IdType="pubmed">22471402</ArticleId></ArticleIdList></Reference><Reference><Citation>Auclair JR, Boggio KJ, Petsko GA, Ringe D, Agar JN. Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2010;107(50):21394&#x2013;21399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003092</ArticleId><ArticleId IdType="pubmed">21098299</ArticleId></ArticleIdList></Reference><Reference><Citation>Amporndanai K, Rogers M, Watanabe S, Yamanaka K, O&#x2019;Neill PM, Hasnain SS. Novel selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis. EBioMedicine. 2020;59:102980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456458</ArticleId><ArticleId IdType="pubmed">32862101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chantadul V, Wright GSA, Amporndanai K, et al. Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy. Communications Biology. 2020;3(1):97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058017</ArticleId><ArticleId IdType="pubmed">32139772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wager TT, Hou X, Verhoest PR, Villalobos A. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem Neurosci. 2016;7(6):767&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pubmed">26991242</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll L, Pattison DI, Davies JB, Anderson RF, Lopez-Alarcon C, Davies MJ. Formation and detection of oxidant-generated tryptophan dimers in peptides and proteins. Free Radic Biol Med. 2017;113:132&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">28962874</ArticleId></ArticleIdList></Reference><Reference><Citation>Crown A, McAlary L, Fagerli E, et al. Tryptophan residue 32 in human Cu-Zn superoxide dismutase modulates prion-like propagation and strain selection. PLoS One. 2020;15(1):e0227655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6991973</ArticleId><ArticleId IdType="pubmed">31999698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill C, Phelan JP, Hatzipetros T, et al. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Sci Rep. 2019;9(1):6724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491559</ArticleId><ArticleId IdType="pubmed">31040321</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjula R, Unni S, Wright GSA, Bharath M. M. S, Padmanabhan B. Rational discovery of a SOD1 tryptophan oxidation inhibitor with therapeutic potential for amyotrophic lateral sclerosis. J Biomol Struct Dyn. 2019;37(15):3936&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pubmed">30286701</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho FR, Iqbal A, Linares E, et al. Oxidation of the tryptophan 32 residue of human superoxide dismutase 1 caused by its bicarbonate-dependent peroxidase activity triggers the non-amyloid aggregation of the enzyme. J Biol Chem. 2014;289(44):30690&#x2013;30701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215247</ArticleId><ArticleId IdType="pubmed">25237191</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E, McAlary L, Farrawell NE, et al. Tryptophan 32-mediated SOD1 aggregation is attenuated by pyrimidine-like compounds in living cells. Sci Rep. 2018;8(1):15590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197196</ArticleId><ArticleId IdType="pubmed">30349065</ArticleId></ArticleIdList></Reference><Reference><Citation>DuVal MG, Hinge VK, Snyder N, et al. Tryptophan 32 mediates SOD1 toxicity in a in vivo motor neuron model of ALS and is a promising target for small molecule therapeutics. Neurobiol Dis. 2019;124:297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">30528257</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Yerbury JJ, Turner BJ, et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc Natl Acad Sci USA. 2014;111(9):3620&#x2013;3625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3948312</ArticleId><ArticleId IdType="pubmed">24550511</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Guest WC, Yanai A, et al. Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proceedings of the National Academy of Sciences. 2011;108(39):16398&#x2013;16403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182705</ArticleId><ArticleId IdType="pubmed">21930926</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DM, Gibbs BF, Kabashi E, Minotti S, Durham HD, Agar JN. Tryptophan 32 potentiates aggregation and cytotoxicity of a copper/zinc superoxide dismutase mutant associated with familial amyotrophic lateral sclerosis. J Biol Chem. 2007;282(22):16329&#x2013;16335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17389599</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa JD, Z&#xe1;rate AM, Fuentes-Lemus E, Davies MJ, L&#xf3;pez-Alarc&#xf3;n C. Formation and characterization of crosslinks, including Tyr&#x2013;Trp species, on one electron oxidation of free Tyr and Trp residues by carbonate radical anion. RSC Adv. 2020;10(43):25786&#x2013;25800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9055361</ArticleId><ArticleId IdType="pubmed">35518626</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinas DB, Rozas P, Mart&#xed;nez Traub F, et al. Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2018;115(32):8209&#x2013;8214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6094144</ArticleId><ArticleId IdType="pubmed">30038021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray SS, Nowak RJ, Brown RH, Lansbury PT. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci USA. 2005;102(10):3639&#x2013;3644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553303</ArticleId><ArticleId IdType="pubmed">15738401</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GSA, Antonyuk SV, Kershaw NM, Strange RW, Samar Hasnain S. Ligand binding and aggregation of pathogenic SOD1. Nat Commun. 2013;4(1):1758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3644087</ArticleId><ArticleId IdType="pubmed">23612299</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonyuk S, Strange RW, Hasnain SS. Structural discovery of small molecule binding sites in Cu&#x2013;Zn human superoxide dismutase familial amyotrophic lateral sclerosis mutants provides insights for lead optimization. J Med Chem. 2010;53(3):1402&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">20067275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kershaw NM, Wright GSA, Sharma R, et al. X-ray crystallography and computational docking for the detection and development of protein&#x2013;ligand interactions. Curr Med Chem. 2013;20(4):569&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">23278398</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjula R, Wright GSA, Strange RW, Padmanabhan B. Assessment of ligand binding at a site relevant to SOD1 oxidation and aggregation. FEBS Lett. 2018;592(10):1725&#x2013;1737.</Citation><ArticleIdList><ArticleId IdType="pubmed">29679384</ArticleId></ArticleIdList></Reference><Reference><Citation>Bono S, Feligioni M, Corbo M. Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy. Mol Neurodegener. 2021;16(1):71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521937</ArticleId><ArticleId IdType="pubmed">34663413</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez-Villegas J, Ferraiuolo L, Mead RJ, Shaw PJ, Cuadrado A, Rojo AI. NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. Free Radic Biol Med. 2021;173:125&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">34314817</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DA, Johnson JA. Nrf2&#x2014;a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med. 2015;88:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809057</ArticleId><ArticleId IdType="pubmed">26281945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanno T, Tanaka K, Yanagisawa Y, et al. A novel small molecule, N-(4-(2-pyridyl)(1,3-thiazol-2-yl))-2-(2,4,6-trimethylphenoxy) acetamide, selectively protects against oxidative stress-induced cell death by activating the Nrf2&#x2013;ARE pathway: therapeutic implications for ALS. Free Radic Biol Med. 2012;53(11):2028&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">23000247</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto G, Kim S, Morimoto RI. Huntingtin and mutant SOD1 form aggregate structures with distinct molecular properties in human cells. J Biol Chem. 2006;281(7):4477&#x2013;4485.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371362</ArticleId></ArticleIdList></Reference><Reference><Citation>Benmohamed R, Arvanites AC, Kim J, et al. Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2011;12(2):87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131116</ArticleId><ArticleId IdType="pubmed">21073276</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Benmohamed R, Arvanites AC, et al. Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorg Med Chem. 2011;19(1):613&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014451</ArticleId><ArticleId IdType="pubmed">21095130</ArticleId></ArticleIdList></Reference><Reference><Citation>Di L, Kerns E, Carter G. Drug-like property concepts in pharmaceutical design. Curr Pharm Des. 2009;15(19):2184&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">19601822</ArticleId></ArticleIdList></Reference><Reference><Citation>Balimane PV, Han Y-H, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 2006;8(1):E1&#x2013;E13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751418</ArticleId><ArticleId IdType="pubmed">16584115</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman RB, Lawton GR, Ranaivo HR, Chico LK, Seo J, Watterson DM. Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood&#x2013;brain barrier penetration. Bioorg Med Chem. 2009;17(21):7593&#x2013;7605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775413</ArticleId><ArticleId IdType="pubmed">19796958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton GR, Ranaivo HR, Chico LK, et al. Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorg Med Chem. 2009;17(6):2371&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775099</ArticleId><ArticleId IdType="pubmed">19268602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Benmohamed R, Kim J, et al. ADME-Guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. J Med Chem. 2012;55(1):515&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8182972</ArticleId><ArticleId IdType="pubmed">22191331</ArticleId></ArticleIdList></Reference><Reference><Citation>Trippier PC, Benmohamed R, Kirsch DR, Silverman RB. Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1. Bioorg Med Chem Lett. 2012;22(21):6647&#x2013;6650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168521</ArticleId><ArticleId IdType="pubmed">23021992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Benmohamed R, Huang H, et al. Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J Med Chem. 2013;56(6):2665&#x2013;2675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627359</ArticleId><ArticleId IdType="pubmed">23445362</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankovic Z CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem. 2015;58(6):2584&#x2013;2608.</Citation><ArticleIdList><ArticleId IdType="pubmed">25494650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhao KT, Fox SG, et al. Tertiary amine pyrazolones and their salts as inhibitors of mutant superoxide dismutase 1-Dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J Med Chem. 2015;58(15):5942&#x2013;5949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537347</ArticleId><ArticleId IdType="pubmed">26186011</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Benmohamed R, Arvanites AC, et al. Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. Bioorg Med Chem. 2012;20(2):1029&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259267</ArticleId><ArticleId IdType="pubmed">22189273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Benmohamed R, Zhang W, et al. Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS. ACS Med Chem Lett. 2012;3(7):584&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402085</ArticleId><ArticleId IdType="pubmed">22837812</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen&#xe7; B, Gautam M, G&#xf6;z&#xfc;tok &#xd6;, et al. Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology. Clin Transl Med, 2021;11(2):e336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898037</ArticleId><ArticleId IdType="pubmed">33634973</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen&#xe7; B, Gautam M, Helmold BR, et al. NU-9 improves health of hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone. Sci Rep. 2022;12(1):5383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967818</ArticleId><ArticleId IdType="pubmed">35354901</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia G, Benmohamed R, Kim J, et al. Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J Med Chem. 2011;54(7):2409&#x2013;2421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074252</ArticleId><ArticleId IdType="pubmed">21375347</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia G, Benmohamed R, Morimoto RI, Kirsch DR, Silverman RB. Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties. Bioorg Med Chem Lett. 2014;24(21):5098&#x2013;5101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250310</ArticleId><ArticleId IdType="pubmed">25266783</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn JM, Melov S. SOD2 in mitochondrial dysfunction and neurodegeneration. Free Radic Biol Med. 2013;62:4&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811078</ArticleId><ArticleId IdType="pubmed">23727323</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehara K, Hasegawa T, Isobe K. A NF-?B p65 subunit is indispensable for activating manganese superoxide: dismutase gene transcription mediated by tumor necrosis factor-? JCB. 2000;77(3):474&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">10760955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiningham KK, Cardozo Z-A, Cook C, et al. All-trans-retinoic acid induces manganese superoxide dismutase in human neuroblastoma through NF-&#x3ba;B. Free Radic Biol Med. 2008;44(8):1610&#x2013;1616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2399892</ArticleId><ArticleId IdType="pubmed">18280257</ArticleId></ArticleIdList></Reference><Reference><Citation>Manuvakhova MS, Johnson GG, White MC, et al. Identification of novel small molecule activators of nuclear factor-&#x3ba;b with neuroprotective action via high-throughput screening. J Neurosci Res. 2011;89(1):58&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280078</ArticleId><ArticleId IdType="pubmed">21046675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew B, Ruiz P, Pathak V, Suto MJ. Development of novel small molecules for the treatment of ALS. Bioorg Med Chem Lett. 2020;30(4):126950.</Citation><ArticleIdList><ArticleId IdType="pubmed">31928838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen S, Lu K, et al. Verapamil ameliorates motor neuron degeneration and improves lifespan in the SOD1G93A mouse model of ALS by enhancing autophagic flux. Aging Dis. 2019;10(6):1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6844595</ArticleId><ArticleId IdType="pubmed">31788329</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan R S, Tsumoto K, Tokunaga M, Tokunaga H, Kita Y, Arakawa T. Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases. Curr Med Chem. 2011;18(1):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21110818</ArticleId></ArticleIdList></Reference><Reference><Citation>Getter T, Zaks I, Barhum Y, et al. A chemical chaperone-based drug candidate is effective in a mouse model of amyotrophic lateral sclerosis (ALS). ChemMedChem. 2015;10(5):850&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">25772747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip P, Sharda PR, Cunningham A, Chakrabartty S, Pande V, Chakrabartty A. Quercitrin and quercetin 3-&#x3b2;-d-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant. Protein Eng Des Sel. 2017;30(6):431&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939853</ArticleId><ArticleId IdType="pubmed">28475686</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfahel L, Argueti-Ostrovsky S, Barel S, et al. 4-Phenylbutyric acid (4-PBA) derivatives prevent SOD1 amyloid aggregation in vitro with no effect on disease progression in SOD1-ALS mice. Int J Mol Sci. 2022;23(16):9403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9409193</ArticleId><ArticleId IdType="pubmed">36012668</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay-Ginsburg S, Di Salvio M, Weitman M, et al. Chemical chaperones targeted to the endoplasmic reticulum (ER) and lysosome prevented neurodegeneration in a C9orf72 repeat expansion drosophila amyotrophic lateral sclerosis (ALS) model. Pharmacological Reports. 2021;73(2):536&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">33661518</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Daniels RD, Gatta AT, Wong LH, Hayes MJ. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics. 2013;29(4):499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH. C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. Acta Neuropathol. 2011;122(6):653&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262229</ArticleId><ArticleId IdType="pubmed">22101324</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong JC, Karydas AM, Goldman JS. Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion. Alzheimers Res Ther. 2012;4(4):27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506941</ArticleId><ArticleId IdType="pubmed">22808918</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry. 2012;83(4):358&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388906</ArticleId><ArticleId IdType="pubmed">22399793</ArticleId></ArticleIdList></Reference><Reference><Citation>Babi&#x107; Leko M, &#x17d;upunski V, Kirincich J, et al. Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion. Behav Neurol. 2019;2019:2909168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350563</ArticleId><ArticleId IdType="pubmed">30774737</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, B&#xe4;umer D, East S, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging. 2014;35(7):1779.e5&#x2013;1779.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd PK, Paulson HL. RNA mediated neurodegeneration in repeat expansion disorders. Ann Neurol. 2009;67:291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852186</ArticleId><ArticleId IdType="pubmed">20373340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng S-M, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339(6125):1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Guo S, Bardhi O, et al. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci USA. 2020;117(31):18591&#x2013;18599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414156</ArticleId><ArticleId IdType="pubmed">32690681</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Mestre AA, et al. C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2&#x3b1; phosphorylation. Nat Commun. 2018;9(1):51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, Glineburg MR, Kearse MG, et al. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Commun. 2017;8(1):2005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-Associated defects in c9FTD/ALS. Neuron. 2014;83(5):1043&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Mergny J-L, Phan A-T, Lacroix L Following G-quartet formation by UV-spectroscopy. FEBS Lett. 1998;435(1):74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">9755862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z-F, Ursu A, Childs-Disney JL, et al. The hairpin form of r(G4C2)exp in c9ALS/FTD is repeat-associated Non-ATG translated and a target for bioactive small molecules. Cell Chemical Biology. 2019;26(2):179&#x2013;190.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386614</ArticleId><ArticleId IdType="pubmed">30503283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ursu A, Wang KW, Bush JA, et al. Structural features of small molecules targeting the RNA repeat expansion that causes genetically defined ALS/FTD. ACS Chem Biol. 15(12), 2020:3112&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7788565</ArticleId><ArticleId IdType="pubmed">33196168</ArticleId></ArticleIdList></Reference><Reference><Citation>Penieres-Carrillo JG, R&#xed;os-Guerra H, P&#xe9;rez-Flores J, et al. Reevaluating the synthesis of 2,5-disubstituted-1 H - benzimidazole derivatives by different green activation techniques and their biological activity as antifungal and antimicrobial inhibitor. J Heterocycl Chem. 2020;57(1):436&#x2013;455.</Citation></Reference><Reference><Citation>Simone R, Balendra R, Moens TG, et al. G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol Med. 2018;10(1):22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordes D, Eggan K, Rubin L COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES. WO/2020/107037.</Citation></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nature Med. 2018;24(3):313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang P-W, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507(7491):195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S, Harper CB, May LM, Coulson EJ, Meunier FA, Osborne SL. Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to Apoptosis-Independent neuronal cell death. PLoS One. 2013;8(3):e60152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609765</ArticleId><ArticleId IdType="pubmed">23544129</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats KA, Seah C, Sahimi A, et al. Small molecule inhibition of PIKFYVE kinase rescues gain- and loss-of-function C9ORF72 ALS/FTD disease processes in vivo bioRxiv 2019;685800.</Citation></Reference><Reference><Citation>Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci. 1997;110(Pt)):1741&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">9264461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M, Chen J, Kuang L, Jin H, Kasarskis EJ, Zhu H. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proceedings of the National Academy of Sciences. 2018;115(51):E11904&#x2013;E11913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6304956</ArticleId><ArticleId IdType="pubmed">30455313</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya T, Maragkakis M. Amyotrophic lateral sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity. Sci Rep. 2018;8(1):15575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197261</ArticleId><ArticleId IdType="pubmed">30349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M. Fused in sarcoma neuropathology in neurodegenerative disease. Cold Spring Harbor Perspect Med. 2017;7(12):a024299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710099</ArticleId><ArticleId IdType="pubmed">28096243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N, Silani V, LeClerc AL, et al. Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology. 2009;73(15):1180&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764725</ArticleId><ArticleId IdType="pubmed">19741215</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler RJ, Lee HO, Poser I, et al. Small molecules for modulating protein driven liquid-liquid phase separation in treating neurodegenerative disease. bioRxiv 2019;721001.</Citation></Reference><Reference><Citation>Rhoads SN, Monahan ZT, Yee DS, et al. The prionlike domain of FUS is multiphosphorylated following DNA damage without altering nuclear localization. Mol Biol Cell. 2018;29(15):1786&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085830</ArticleId><ArticleId IdType="pubmed">29897835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garc&#xed;a-Mart&#xed;nez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69(6):3584&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J Neurochem. 2016;138:95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS mutations disrupt phase separation mediated by &#x3b1;-Helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016;24(9):1537&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C-F, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007;113(5):535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">17333220</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proceedings of the National Academy of Sciences. 2008;105(17):6439&#x2013;6444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284(30):20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201(3):361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang MY, Markmiller S, Vu AQ, et al. Small-molecule modulation of TDP-43 recruitment to stress granules prevents persistent TDP-43 accumulation in ALS/FTD. Neuron. 2019;103(5):802&#x2013;819.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728177</ArticleId><ArticleId IdType="pubmed">31272829</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett DA, Vacca JP. Preparation of compounds for modulating inclusion formation and stress granules in cells and their use in treatment of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmic diseases and viral infections. Aquinnah Pharmaceuticals, Inc.; 2018.</Citation></Reference><Reference><Citation>Larsen GR, Weigele M, Vacca J Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases. WO2016090317A1WO2016090317A1; 2016.</Citation></Reference><Reference><Citation>Larsen GR, Weigele M, Vacca JP, Burnett DA, Ripka A. Preparation of azacyclic compounds, compositions and methods of use against stress granules. Aquinnah Pharmaceuticals, Inc.; 2017.</Citation></Reference><Reference><Citation>Fran&#xe7;ois-Moutal L, Felemban R, Scott DD, et al. Small molecule targeting TDP-43&#x2019;s RNA recognition motifs reduces locomotor defects in a drosophila model of amyotrophic lateral sclerosis (ALS). ACS Chem Biol. 2019;14(9):2006&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6911355</ArticleId><ArticleId IdType="pubmed">31241884</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado IG, Redondo M, Bello ML, et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem. 2014;57(6):2755&#x2013;2772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969104</ArticleId><ArticleId IdType="pubmed">24592867</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci. 2010;30(48):16208&#x2013;16219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3075589</ArticleId><ArticleId IdType="pubmed">21123567</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117(2):137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Choksi DK, Roy B, Chatterjee S, et al. TDP-43 Phosphorylation by casein kinase I&#x3b5; promotes oligomerization and enhances toxicity in vivo. Hum Mol Gen. 2014;23(4):1025&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">24105464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks DA, Cross LL, Williamson R, Rattray M. Endoplasmic reticulum stress signalling induces casein kinase 1-dependent formation of cytosolic TDP-43 inclusions in motor neuron-like cells. Neurochem Res. 2020;45(6):1354&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260270</ArticleId><ArticleId IdType="pubmed">31280399</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Suzuki G, Tanaka Y, et al. Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1&#x3b4; triggers mislocalization and accumulation of TDP-43. J Biol Chem. 2016;291(11):5473&#x2013;5483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervishi I, Ozdinler PH. Incorporating upper motor neuron health in ALS drug discovery. Drug Discovery Today. 2018;23(3):696&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849515</ArticleId><ArticleId IdType="pubmed">29331501</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, Jara JH, Kocak N, et al. Mitochondria, ER, and nuclear membrane defects reveal early mechanisms for upper motor neuron vulnerability with respect to TDP-43 pathology. Acta Neuropathol. 2019;137(1):47&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339587</ArticleId><ArticleId IdType="pubmed">30450515</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F, Amadio S, Volont&#xe9; C. Fly for ALS: drosophila modeling on the route to amyotrophic lateral sclerosis modifiers. Cell Mol Life Sci. 2021;78(17&#x2013;18):6143&#x2013;6160.</Citation><ArticleIdList><ArticleId IdType="pubmed">34322715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T, Zerbo RA, Balbi M, et al. Nearly 30 years of animal models to study amyotrophic lateral sclerosis: a historical overview and future perspectives. Int J Mol Sci. 2021;22(22):12236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8619465</ArticleId><ArticleId IdType="pubmed">34830115</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F, Amadio S, Volont&#xe9; C. Where and why modeling amyotrophic lateral sclerosis. Int J Mol Sci. 2021;22(8):3977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8070525</ArticleId><ArticleId IdType="pubmed">33921446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C, Palma AS, Almeida R, et al. Establishment of a cell model of ALS disease: Golgi apparatus disruption occurs independently from apoptosis. Biotechnol Lett. 2008;30(4):603&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">18004513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, Cozzolino M, Crosio C, et al. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci USA. 2006;103(37):13860&#x2013;13865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557633</ArticleId><ArticleId IdType="pubmed">16945901</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzardini M, Mangolini A, Lupi M, Ubezio P, Bendotti C, Cantoni L. Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells. J Neurol Sci. 2005;232(1&#x2013;2):95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850589</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S, Heath PR, Kirby J, et al. Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways. J Biol Chem. 2003;278(8):6371&#x2013;6383.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475980</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR, Menzies FM, Manning P, et al. Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. Amyotrophic Lateral Sclerosis. 2002;3(2):75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12215229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman NR, Durham HD, Blusztajn JK, et al. Neuroblastoma &#xd7; spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn. 1992;194(3):209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini M, Bayona-Feliu A, Sproviero D, Barroso SI, Cereda C, Aguilera A. TDP-43 mutations link amyotrophic lateral sclerosis with R-loop homeostasis and R loop-mediated DNA damage. PLoS Genet. 2020;16(12):e1009260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755276</ArticleId><ArticleId IdType="pubmed">33301444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Liu X, Wang S, Sun G, Zhao R, Lu H. SecinH3 attenuates TDP-43 p.Q331K-Induced neuronal toxicity by suppressing endoplasmic reticulum stress and enhancing autophagic flux. IUBMB Life. 2019;71(2):192&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">30376609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala G, Beretta S, Ceresa C, et al. Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis. Neurochem Int. 2005;46(3):227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">15670639</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd JD, Lee-Armandt JP, Feiler MS, et al. A high-content screen identifies novel compounds that inhibit Stress-Induced TDP-43 cellular aggregation and associated cytotoxicity. SLAS Discovery. 2014;19(1):44&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913261</ArticleId><ArticleId IdType="pubmed">24019256</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent AM, Backus C, Taubman AA, Feldman EL. Identification of candidate drugs for the treatment of ALS. Amyotrophic Lateral Sclerosis. 2005;6(1):29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16036423</ArticleId></ArticleIdList></Reference><Reference><Citation>Thams S, Lowry ER, Larraufie M-H, et al. A stem cell-based screening platform identifies compounds that desensitize motor neurons to endoplasmic reticulum stress. Mol Ther. 2019;27(1):87&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6318783</ArticleId><ArticleId IdType="pubmed">30446391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YM, Gupta SK, Kim KJ, et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013;12(6):713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707511</ArticleId><ArticleId IdType="pubmed">23602540</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Roet KCD, Zhang L, et al. Human amyotrophic lateral sclerosis excitability phenotype screen: target discovery and validation. Cell Rep. 2021;35(10):109224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209673</ArticleId><ArticleId IdType="pubmed">34107252</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt MF, Martinez FJ, Wright S, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci. 2013;56:355&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao A, Pan Y, Cai S. Patient-Specific cells for modeling and decoding amyotrophic lateral sclerosis: advances and challenges. Stem Cell Rev Rep. 2020;16(3):482&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">31916190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura G, Iemmolo R, Attaguile GA, et al. iPSCs: a preclinical drug research tool for neurological disorders. Int J Mol Sci. 2021;22(9):4596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8123805</ArticleId><ArticleId IdType="pubmed">33925625</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannis P, Inoue H. ALS, a cellular whodunit on motor neuron degeneration. Mol Cell Neurosci. 2020;107:103524.</Citation><ArticleIdList><ArticleId IdType="pubmed">32629110</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-Y, Ting H-C, Liu C-A, et al. Induced pluripotent stem cell (iPSC)-Based neurodegenerative disease models for phenotype recapitulation and drug screening. Molecules. 2020;25(8):2000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7221979</ArticleId><ArticleId IdType="pubmed">32344649</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E, Karpf L, Bohl D. Neuroinflammation in amyotrophic lateral sclerosis and frontotemporal dementia and the interest of induced pluripotent stem cells to study immune cells interactions with neurons. Front Mol Neurosci. 2021;14:767041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712677</ArticleId><ArticleId IdType="pubmed">34970118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrot J, Imhof S, Wainger BJ. Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs. Neurobiol Dis. 2020;134:104680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7002167</ArticleId><ArticleId IdType="pubmed">31759135</ArticleId></ArticleIdList></Reference><Reference><Citation>Lines G, Casey JM, Preza E, Wray S. Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells. Mol Cell Neurosci. 2020;109:103553.</Citation><ArticleIdList><ArticleId IdType="pubmed">32956830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohl D, Pochet R, Mitrecic D, Nicaise C. Modelling and treating amyotrophic lateral sclerosis through induced&#x2014;pluripotent stem cells technology. Curr Stem Cell Res Ther. 2016;11(4):301&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">26018231</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Huang EJ. Modeling ALS and FTD with iPSC-derived neurons. Brain Res. 2017;1656:88&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833714</ArticleId><ArticleId IdType="pubmed">26462653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E, Sandoe J, Williams LA, et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14(6):781&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard J-P, Maragakis NJ. Induced pluripotent stem cells from ALS patients for disease modeling. Brain Res. 2015;1607:15&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362997</ArticleId><ArticleId IdType="pubmed">25223906</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin A-C, Burr K, Borooah S, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6(1):5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med. 2012;4(145):145ra104.</Citation><ArticleIdList><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Maragakis NJ. Mini-review: induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neurosci Lett. 2021;755:135911.</Citation><ArticleIdList><ArticleId IdType="pubmed">33892003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-H, Liu J-W, Lin S-Z, Harn H-J, Chiou T-W. Advances in patient-specific induced pluripotent stem cells shed light on drug discovery for amyotrophic lateral sclerosis. Cell Transplant. 2018;27(9):1301&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168987</ArticleId><ArticleId IdType="pubmed">30033758</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Models &amp; Mech. 2017;10(5):537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Myszczynska M, Ferraiuolo L. New in vitro models to study amyotrophic lateral sclerosis. Brain Pathol. 2016;26(2):258&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029155</ArticleId><ArticleId IdType="pubmed">26780562</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, Thompson T, Li J, et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neurosci. 2022;25(2):226&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Thonhoff JR, et al. Immunosuppressive functions of M2 macrophages derived from iPSCs of patients with ALS and healthy controls. iScience. 2020;23(6):101192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286967</ArticleId><ArticleId IdType="pubmed">32521508</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W, Rajendran L. Concise review: modeling neurodegenerative diseases with human pluripotent stem cell-derived microglia. Stem Cells. 2019;37(6):724&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6849818</ArticleId><ArticleId IdType="pubmed">30801863</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T, Uzel SGM, Kamm RD. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci Adv. 2018;4(10):eaat5847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179377</ArticleId><ArticleId IdType="pubmed">30324134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H-Y, Cho H, Lee LP. Human mini-brain models. Nat Biomed Eng. 2021;5(1):11&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33318650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattorelli N, Martinez-Muriana A, Wolfs L, Geric I, De Strooper B, Mancuso R. Stem-cell-derived human microglia transplanted into mouse brain to study human disease. Nat Protoc. 2021;16(2):1013&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">33424025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmann J, Blurton-Jones M. Human iPSC-derived microglia: A growing toolset to study the brain&#x2019;s innate immune cells. GLIA. 2020;68(4):721&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813153</ArticleId><ArticleId IdType="pubmed">31926038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasvoina MV, Gen&#xe7; B, Jara JH, et al. eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model. J Neurosci. 2013;33(18):7890&#x2013;7904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963467</ArticleId><ArticleId IdType="pubmed">23637180</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>